• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

    6.580 -0.450 (-6.40%)
    Streaming Delayed Price Updated: 10:30 AM EST, Mar 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 41,967
    Open 6.880
    Bid (Size) 6.560 (100)
    Ask (Size) 6.740 (100)
    Prev. Close 7.030
    Today's Range 6.500 - 7.075
    52wk Range 3.760 - 17.25
    Shares Outstanding 42,940,089
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
    From Aligos Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    -27.9%
    -27.9%
    1 Month
    -18.5%
    -18.5%
    3 Month
    -29.2%
    -29.2%
    6 Month
    -38.0%
    -38.0%
    1 Year
    -54.6%
    -54.6%

    More News

    Read More
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 6, 2025 ↗
    Via Benzinga
    News headline image
    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Presents Positive Data at HEP-DART 2025
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Present at Upcoming Investor Conferences
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is Aligos Therapeutics, Inc. - Common stock publicly traded?
    Yes, Aligos Therapeutics, Inc. - Common stock is publicly traded.
    What exchange does Aligos Therapeutics, Inc. - Common stock trade on?
    Aligos Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Aligos Therapeutics, Inc. - Common stock?
    The ticker symbol for Aligos Therapeutics, Inc. - Common stock is ALGS on the Nasdaq Stock Market
    What is the current price of Aligos Therapeutics, Inc. - Common stock?
    The current price of Aligos Therapeutics, Inc. - Common stock is 6.580
    When was Aligos Therapeutics, Inc. - Common stock last traded?
    The last trade of Aligos Therapeutics, Inc. - Common stock was at 03/02/26 10:30 AM ET
    What is the market capitalization of Aligos Therapeutics, Inc. - Common stock?
    The market capitalization of Aligos Therapeutics, Inc. - Common stock is 282.55M
    How many shares of Aligos Therapeutics, Inc. - Common stock are outstanding?
    Aligos Therapeutics, Inc. - Common stock has 283M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.